Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

Casdin Capital 13F Holdings (Q3 2026)

According to its SEC 13F filed on Nov 16, 2026, Casdin Capital reported 47 long positions worth $2.30B as of Sep 30, 2026. RVMD is 23.0% of the portfolio and the top 10 holdings are 76%. Against Q2 2026 it opened 6 new positions, added to 8, trimmed 5 and exited 2. 7 holdings have a dated FDA decision or data readout in the next 90 days, and 11 more expect one in a stated window such as "H2 2026".

Data as of Sep 30, 2026SEC 13F filed Nov 16, 2026Next filing (Q4 2026) due Feb 16, 2027Value as filed; options at underlying sharesLong positions only
Market Value$ 2.30 B13F value, as filed
QoQ Changes14.91 %13F value vs the previous quarter
Holdings48 47 stocks · 0 option positions
PeriodQ3 202613F reporting quarter
Holdings in Top 20 % top 10: 76% of the portfolio
Activity vs Q2 20266 new8 added · 5 trimmed · 2 exits
Catalysts ahead7dated in 90 days · +11 in a stated window

Catalysts ahead in this portfolio

Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval

Nov 18, 2026NTLAPhase 1 data presentation: Nexiguran Ziclumeran (nex-z)PoA 35%
Nov 19, 2026ANLPhase 1 data presentation: AN4035PoA 8%

5 more with a subscription

What changed vs Q2 2026

ORICOric Pharmaceuticals, Inc.$17M
BIIBBiogen$11M

Full lists with a subscription

Portfolio over time

13F value by quarter, Q1 2021 to Q3 2026

Q1 2021: $3.36BQ3 2026: $2.30B

By company stage (share of value)

Commercial 37%Other 37%Clinical 26%

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 48. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
MRNA
MRNA
MODERNA INC
75.00 K
14.44 M
0.6
Unchanged
Commercial
Dec 12, 2026
Phase 1/2 data presentation
PACB
PACB
PACIFIC BIOSCIENCES CALIF IN
723.77 K
1.72 M
0.1
Unchanged
—
None in 90 days
GRAL
GRAL
GRAIL INC
680.00 K
95.28 M
4.2
Added +42%
—
None in 90 days
PRME
PRME
PRIME MEDICINE INC
3.17 M
9.68 M
0.4
Unchanged
Clinical
None in 90 days
DNA
DNA
GINKGO BIOWORKS HOLDINGS INC
36.49 K
468.20 K
0
Unchanged
—
None in 90 days
MAZE
MAZE
MAZE THERAPEUTICS INC
843.86 K
22.94 M
1
Unchanged
Clinical
None in 90 days

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about Casdin Capital's 13F

What does Casdin Capital own?

47 stocks worth $2.30B at Sep 30, 2026, as reported in its 13F, led by RVMD (23.0% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q2 2026: 6 new positions, 8 increases, 5 reductions and 2 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q4 2026) is due Feb 16, 2027.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by Casdin Capital, LLC, accession 0000919574-26-008113, filed Nov 16, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.